Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
686.4 INR | +1.52% | +0.83% | +25.76% |
May. 03 | Jubilant Pharmova Appoints CEO for Radiopharma Business | MT |
Apr. 25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Sales 2022 | 61.3B 735M | Sales 2023 | 62.82B 754M | Capitalization | 44.42B 533M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.66M | Net income 2023 | -610M -7.32M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +1.52% | ||
1 week | +0.83% | ||
Current month | +1.98% | ||
1 month | +18.70% | ||
3 months | +15.61% | ||
6 months | +73.76% | ||
Current year | +25.76% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.67% | - | |
0.00% | 117 M€ | +2.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 686.4 | +1.52% | 7,359 |
24-05-02 | 676 | +0.45% | 10,055 |
24-04-30 | 673 | -1.91% | 22,391 |
24-04-29 | 686.2 | +0.80% | 26,335 |
24-04-26 | 680.7 | +0.60% | 13,544 |
Delayed Quote Bombay S.E., May 03, 2024 at 06:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+25.76% | 1.29B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- JUBLPHARMA Stock